NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019

被引：218

作者：

Armstrong, Deborah K. ^{[1
]}

Alvarez, Ronald D. ^{[2
]}

Bakkum-Gamez, Jamie N. ^{[3
]}

Barroilhet, Lisa ^{[4
]}

Behbakht, Kian ^{[5
]}

Berchuck, Andrew ^{[6
]}

Berek, Jonathan S. ^{[7
]}

Chen, Lee-may ^{[8
]}

Cristea, Mihaela ^{[9
]}

DeRosa, Marie

ElNaggar, Adam C. ^{[10
]}

Gershenson, David M. ^{[11
]}

Gray, Heidi J. ^{[12
]}

Hakam, Ardeshir ^{[13
]}

Jain, Angela ^{[14
]}

Leath, Charles A., III ^{[15
]}

Liu, Joyce ^{[16
]}

Mahdi, Haider ^{[17
,18
]}

Matei, Daniela ^{[19
]}

McHale, Michael ^{[20
]}

McLean, Karen ^{[21
]}

O'Malley, David M. ^{[22
,23
]}

Penson, Richard T. ^{[24
]}

Percac-Lima, Sanja ^{[24
]}

Ratner, Elena ^{[25
]}

Remmenga, Steven W. ^{[26
]}

Sabbatini, Paul ^{[27
]}

Werner, Theresa L. ^{[28
]}

Zsiros, Emese ^{[29
]}

Burns, Jennifer L. ^{[30
]}

Engh, Anita M. ^{[30
]}

机构：

[1] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA

[2] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[3] Mayo Clin, Canc Ctr, Rochester, MN USA

[4] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53706 USA

[5] Univ Colorado, Canc Ctr, Boulder, CO 80309 USA

[6] Duke Canc Inst, Durham, NC USA

[7] Stanford Canc Inst, Stanford, CA USA

[8] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[9] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

[10] Univ Tennessee, St Jude Childrens Res Hosp, Hlth Sci Ctr, Knoxville, TN 37996 USA

[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[12] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA

[13] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[14] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[15] Univ Alabama Birmingham, Comprehens Canc Ctr, Birmingham, AL USA

[16] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA

[17] Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA

[18] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA

[19] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA

[20] UC San Diego Moores Canc Ctr, San Diego, CA USA

[21] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[22] Ohio State Univ, Comprehens Canc Ctr, James Canc Hosp, Columbus, OH 43210 USA

[23] Solove Res Inst, Columbus, OH USA

[24] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA

[25] Yale Canc Ctr, Smilow Canc Hosp, New Haven, CT USA

[26] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA

[27] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[28] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

[29] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[30] Natl Comprehens Canc Network, Ft Washington, PA USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2019年 / 17卷 / 08期

关键词：

HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; ADVANCED EPITHELIAL OVARIAN; INTERVAL DEBULKING SURGERY; EXTENSIVE CYTOREDUCTIVE SURGERY; GYNECOLOGIC-ONCOLOGY-GROUP; III RANDOMIZED-TRIAL; NEOADJUVANT CHEMOTHERAPY; STAGE-III; PHASE-II; MAINTENANCE THERAPY;

D O I：

10.6004/jnccn.2019.0039

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years from diagnosis. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. The best outcomes are observed in patients whose primary treatment includes complete resection of all visible disease plus combination platinum-based chemotherapy. Research efforts are focused on primary neoadjuvant treatments that may improve resectability, as well as systemic therapies providing improved long-term survival. These NCCN Guidelines Insights focus on recent updates to neoadjuvant chemotherapy recommendations, including the addition of hyperthermic intraperitoneal chemotherapy, and the role of PARP inhibitors and bevacizumab as maintenance therapy options in select patients who have completed primary chemotherapy.

引用

页码：896 / +

页数：26

共 79 条

[1] Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].

Alberts, DS ;

Liu, PY ;

Hannigan, EV ;

OToole, R ;

Williams, SD ;

Young, JA ;

Franklin, EW ;

ClarkePearson, DL ;

Malviya, VK ;

DuBeshter, B ;

Adelson, MD ;

Hoskins, WJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955

[2]

[Anonymous], 2019, BEV INJ PRESCR INF

[3]

[Anonymous], GYNECOL ONCOL S1

[4]

[Anonymous], 2017, PAZ TABL PRESCR INF

[5]

[Anonymous], 2018, OL TABL PRESCR INF

[6]

[Anonymous], 2010, GYNECOL ONCOL

[7]

[Anonymous], 2018, RUC TABL PRESCR INF

[8]

[Anonymous], 2017, NIR CAPS PRESCR INF

[9] Evaluation of Extensive Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Epithelial Ovarian Cancer [J].

Ansaloni, Luca ;

Agnoletti, Vanni ;

Amadori, Andrea ;

Catena, Fausto ;

Cavaliere, Davide ;

Coccolini, Federico ;

De Iaco, Pierandrea ;

Di Battista, Monica ;

Framarini, Massimo ;

Gazzotti, Filippo ;

Ghermandi, Claudio ;

Kopf, Barbara ;

Saponara, Maristella ;

Tauceri, Francesca ;

Vallicelli, Carlo ;

Verdecchia, Giorgio Maria ;

Pinna, Antonio Daniele .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2012, 22 (05) :778-785

[10] Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].

Armstrong, DK ;

Bundy, B ;

Wenzel, L ;

Huang, HQ ;

Baergen, R ;

Lele, S ;

Copeland, LJ ;

Walker, JL ;

Burger, RA .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43

← 1 2 3 4 5 6 7 8 →